@article{3141416,
    title = "Catatonia as a risk factor for the development of neuroleptic malignant
syndrome: Report of a case following treatment with clozapine",
    author = "Paparrigopoulos, Thomas and Tzavellas, Elias and Ferentinos, Panagiotis and and Mourikis, Iraklis and Liappas, John",
    journal = "World Journal of Biological Psychiatry",
    year = "2009",
    volume = "10",
    number = "1",
    pages = "70-73",
    publisher = "TAYLOR & FRANCIS LTD LONDON",
    issn = "1562-2975, 1814-1412",
    doi = "10.1080/15622970701287369",
    keywords = "Catatonia; clozapine; neuroleptic malignant syndrome; risk factor",
    abstract = "Catatonia is characterized by the predominance of psychomotor
abnormalities and shares many clinical, biological and treatment
response features with the neuroleptic malignant syndrome (NMS), a rare
adverse reaction to psychoactive medications. It has been advocated that
the two conditions should be placed along the same spectrum of
disorders. A case of a 49-year-old woman, who developed NMS while on low
dose clozapine soon after recovering from catatonia, is presented. The
potential relationship between catatonia and NMS is discussed in the
light of the existing literature, and attention is drawn to the risk for
clozapine-induced NMS in catatonic patients."
}